Orbimed Advisors LLC Portfolio Holdings

Orbimed Advisors LLC

  • $4.24 Billion
  • Q3 2024

Orbimed Advisors LLC has filed its 13F form on November 14, 2024 for Q3 2024 where it was disclosed a total value porftolio of $4.24 Billion distributed in 119 stocks.

Among their holdings, we can observe that their the top five positions include companies like: Edgewise Therapeutics, Inc. with a value of $401M, Eli Lilly & CO with a value of $299M, Boston Scientific Corp with a value of $274M, Intuitive Surgical Inc with a value of $213M, and Biogen Inc. with a value of $158M.

Examining the 13F form we can see an increase of $93.7M in the current position value, from $4.15B to 4.24B.

Orbimed Advisors LLC is based out at San Diego, CA

Below you can find more details about Orbimed Advisors LLC portfolio as well as his latest detailed transactions.

Portfolio value $4.24 Billion
Healthcare: $4.24 Billion

Stock Holdings Table

Stock Market Cap. Holding Value (Reported) # of Shares. Last Trade Trade History
$34.9M
$22.6 Million 0.53% of portfolio
10,909,256
Q2 2023 Added 8.66%
$666M
$18.1 Million 0.43% of portfolio
768,638
Q1 2024 New
$574M
$17.9 Million 0.42% of portfolio
1,070,055
Q3 2024 Reduced 6.76%
$153M
$17.3 Million 0.41% of portfolio
11,024,000
Q3 2024 Added 88.57%
$38.8M
$16.5 Million 0.39% of portfolio
11,447,140
Q1 2024 Added 37.55%
$10.1B
$15 Million 0.35% of portfolio
44,900
Q3 2024 New
$154M
$14.3 Million 0.34% of portfolio
4,533,801
Q3 2024 Added 5.03%
$111B
$12.7 Million 0.3% of portfolio
151,700
Q3 2024 New
$24.8B
$12.2 Million 0.29% of portfolio
103,000
Q3 2024 New
$2.63B
$11.8 Million 0.28% of portfolio
764,600
Q3 2024 New
$119M
$11.4 Million 0.27% of portfolio
3,322,488
Q3 2021 Reduced 3.03%
$761M
$10.8 Million 0.26% of portfolio
4,180,768
Q3 2021 Reduced 32.82%
$71.6M
$9.65 Million 0.23% of portfolio
6,475,291
Q4 2023 Reduced 1.34%
$255M
$8.4 Million 0.2% of portfolio
6,086,001
Q3 2024 Reduced 4.98%
$3.01B
$7.46 Million 0.18% of portfolio
351,618
Q3 2024 New
$27.8M
$6.88 Million 0.16% of portfolio
9,822,876
Q3 2024 Reduced 2.98%
$106M
$6.82 Million 0.16% of portfolio
797,358
Q3 2024 New
$215M
$5.88 Million 0.14% of portfolio
1,680,580
Q3 2024 Added 24.0%
$61.6M
$6.12 Million 0.14% of portfolio
3,539,358
Q4 2023 Added 11.09%
$2.69B
$6.09 Million 0.14% of portfolio
570,300
Q1 2024 Reduced 29.24%
$1.44B
$5.95 Million 0.14% of portfolio
742,300
Q3 2024 Reduced 30.91%
$55.9M
$5.47 Million 0.13% of portfolio
2,161,185
Q3 2024 Reduced 12.06%
$21.1M
$5.72 Million 0.13% of portfolio
2,133,405
Q4 2023 Added 14.67%
$812M
$5.67 Million 0.13% of portfolio
170,000
Q3 2024 New
$505M
$5.72 Million 0.13% of portfolio
1,728,300
Q3 2024 Reduced 28.75%
$24.7M
$4.78 Million 0.11% of portfolio
7,133,515
Q2 2023 Added 22.62%
$4.57B
$4.27 Million 0.1% of portfolio
23,500
Q3 2024 Reduced 21.58%
$55.8M
$3.04 Million 0.07% of portfolio
2,000,000
Q1 2024 New
$18.7M
$2.73 Million 0.06% of portfolio
1,741,273
Q3 2024 Reduced 22.31%
$36.1M
$1.56 Million 0.04% of portfolio
1,141,200
Q1 2024 Reduced 57.91%
$85.4M
$1.53 Million 0.04% of portfolio
448,891
Q4 2022 Added 9.17%
$512M
$1.48 Million 0.03% of portfolio
1,927,000
Q4 2023 Reduced 64.73%
$12.6M
$564,000 0.01% of portfolio
941,275
Q1 2024 Reduced 37.25%
$416M
$229,000 0.01% of portfolio
80,420
Q1 2024 New
Arrivent Biopharma Inc
-
$0 0.0% of portfolio
-
Q1 2024 New
Mineralys Therapeutics Inc
-
$0 0.0% of portfolio
-
Q3 2024 Reduced 0.91%
Avalo Therapeutics Inc
-
$0 0.0% of portfolio
-
Q3 2024 New
Ardent Health Partners Inc
-
$0 0.0% of portfolio
-
Q3 2024 New
Apogee Therapeutics Inc
-
$0 0.0% of portfolio
-
Q2 2024 Reduced 47.26%
Verastem Inc
-
$0 0.0% of portfolio
-
Q3 2024 Added 87.2%
Acelyrin Inc
-
$0 0.0% of portfolio
-
Q4 2023 Reduced 24.87%
Mbx Biosciences Inc
-
$0 0.0% of portfolio
-
Q3 2024 New
$0
$0 0.0% of portfolio
8,288,510
Q3 2024 Reduced 10.31%
Traws Pharma Inc
-
$0 0.0% of portfolio
-
Q3 2024 New
Bicara Therapeutics Inc
-
$0 0.0% of portfolio
-
Q3 2024 New
Ikena Oncology Inc
-
$0 0.0% of portfolio
-
Q3 2023 Added 1.29%
Q32 Bio Inc
-
$0 0.0% of portfolio
-
Q1 2024 New
Instil Bio Inc
-
$0 0.0% of portfolio
-
Q3 2024 New
Enliven Therapeutics Inc
-
$0 0.0% of portfolio
-
Q2 2024 Reduced 11.54%

Summary

  • Portfolio
  • No. of Stocks 119
  • Current Value $4.24 Billion
  • Prior Value $4.15 Billion
  • Filing
  • Period Q3 2024
  • Filing Date November 14, 2024
  • Form Type 13F-HR
  • Activity in Q3 2024
  • New Purchases 19 stocks
  • Additional Purchases 19 stocks
  • Sold out of 0 stocks
  • Reduced holdings in 29 stocks
Track This Portfolio

Track Orbimed Advisors LLC Portfolio

Follow Orbimed Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Orbimed Advisors LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email